All In Biotech

Drug Trial Radar · NCT07623642

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

An Open-Label, Multicenter, Non-Randomized, Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

227

Planned (sponsor's estimate)

Start

Jun 2, 2026

Primary completion

Jun 15, 2028

Study completion Aug 15, 2029

Sponsor

Lead sponsor
GV20 TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors who are refractory to, intolerant of, or ineligible for standard of care.

Conditions

  • Uterine Cervical Neoplasms
  • Triple Negative Breast Neoplasms
  • Prostatic Neoplasms
  • Squamous Cell Carcinoma of Head and Neck
  • Esophageal Squamous Cell Carcinoma
  • Cholangiocarcinoma
  • Gallbladder Neoplasms
  • Colorectal Neoplasms
  • Pancreatic Ductal Adenocarcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Small Cell Lung Carcinoma

Interventions

  • GV20-0251Drug

    GV20-0251 10/20 mg/kg or SRC-recommended dose in combination with anti-PD-1, Q3W; Part B: RP2D + standard dose anti-PD-1, Q3W.

  • anti-PD-1 monoclonal antibodiesDrug

    anti-PD-1 monoclonal antibodies 200 mg IV Q3W; C1D1 infusion ≥ 60 min, subsequent infusions may be shortened to ≥ 30 min; administered prior to GV20-0251.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs) and Treatment-Emergent Adverse Events (TEAEs) in Combination with Anti-PD-1 Monoclonal AntibodyTime frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) through 30 days after end of treatment, up to 24 months
  2. Evaluate the anti-tumor activity of GV20-0251 in combination with anti-PD-1 monoclonal antibodyTime frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) until disease progression or end of study (whichever occurs first, up to 24 months)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.